SCHEMBL1758710

SCHEMBL1758710

FC(F)(F)Cn1cc(-c2ccncc2)c(-c2ccc(OCc3ccccc3)cc2)n1

nearest known ligand 0.71

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 7/20 0.71
PDE4A P27815 1/20 0.50
PDE4B Q07343 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3269569 0.88 PDE10A (0.56) PDE10APDE4APDE4B
SCHEMBL1758443 0.86 PDE10A (0.70) PDE10A
SCHEMBL24951258 0.85 PDE10A (0.53) PDE10APDE4APDE4B
SCHEMBL17088202 0.84 PDE10A (0.57) PDE10A
SCHEMBL3274824 0.84 PDE10A (0.81) PDE10APDE4APDE4B
SCHEMBL30123240 0.84 PDE10A (0.81) PDE10APDE4APDE4B
SCHEMBL3270782 0.83 PDE10A (1.00) PDE10APDE4APDE4B
SCHEMBL29368113 0.83 PDE10A (1.00) PDE10APDE4APDE4B
SCHEMBL1758488 0.83 PDE10A (0.52) PDE10APDE4APDE4B
SCHEMBL4861110 0.81 PDE10A (0.69) PDE10APDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240336591-A1 ORGANIC PYRIDINE-PYRAZOLE COMPOUNDS AND THEIR USES Benevolentai Cambridge Limited (GB) 2024-10-10 US disclosed
WO-2023007184-A1 ORGANIC PYRIDINE-PYRAZOLE COMPOUNDS AND THEIR USES Benevolentai Cambridge Limited (GB) 2023-02-02 WO disclosed
US-8852554-B2 Radiolabelled PDE10 ligands JANSSEN PHARMACEUTICA NV (BE) 2014-10-07 US disclosed
US-8852554-B2 Radiolabelled PDE10 ligands JANSSEN PHARMACEUTICA NV (BE) 2014-10-07 US disclosed
US-8852554-B2 Radiolabelled PDE10 ligands JANSSEN PHARMACEUTICA NV (BE) 2014-10-07 US disclosed
EP-2493513-B1 RADIOLABELLED PDE10 LIGANDS JANSSEN PHARMACEUTICA NV (BE) 2014-07-30 EP disclosed
EP-2493513-B1 RADIOLABELLED PDE10 LIGANDS JANSSEN PHARMACEUTICA NV (BE) 2014-07-30 EP disclosed
EP-2493513-A1 RADIOLABELLED PDE10 LIGANDS Janssen Pharmaceutica, N.V. (BE) 2012-09-05 EP disclosed
US-20120213703-A1 RADIOLABELLED PDE10 LIGANDS JANSSEN-CILAG S.A., EDIFICIO JOHNSON & JOHNSON (ES) 2012-08-23 US disclosed
US-20120213703-A1 RADIOLABELLED PDE10 LIGANDS JANSSEN-CILAG S.A., EDIFICIO JOHNSON & JOHNSON (ES) 2012-08-23 US disclosed
US-7825254-B2 Heteroaromatic quinoline compounds PFIZER INC. (US) 2010-11-02 US disclosed
EP-1841757-B1 HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS PFIZER PROD INC (US) 2010-06-30 EP disclosed
EP-1979343-A2 BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS Pfizer Products Inc. (US) 2008-10-15 EP disclosed
US-7429665-B2 Heteroaromatic quinoline compounds PFIZER INC (US) 2008-09-30 US disclosed
US-20080214607-A1 HETEROAROMATIC QUINOLINE COMPOUNDS PFIZER INC 2008-09-04 US disclosed
EP-1841757-A2 HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS Pfizer Products Incorporated (US) 2007-10-10 EP disclosed
WO-2007077490-A2 BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS PFIZER PRODUCTS INC. (US) 2007-07-12 WO disclosed
US-20070155779-A1 BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS PFIZER INC 2007-07-05 US disclosed
US-20060154931-A1 Heteroaromatic quinoline compounds PFIZER INC 2006-07-13 US disclosed
WO-2006072828-A2 HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS PFIZER PRODUCTS INC. (US) 2006-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154931-A1 Heteroaromatic quinoline compounds PDE12, PDE7A, PDE4A PDE10A 8/4885PDE4A 3/4885PDE4B 7/4885
US-20240336591-A1 ORGANIC PYRIDINE-PYRAZOLE COMPOUNDS AND THEIR USES ALPI, NOD1, PNPO PDE10A 963/4885PDE4A 1130/4885PDE4B 602/4885
US-20070155779-A1 BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS PDE12, PDE10A, PDE7A PDE10A 2/4885PDE4A 4/4885PDE4B 11/4885
US-20080214607-A1 HETEROAROMATIC QUINOLINE COMPOUNDS PDE12, PDE7A, PDE4A PDE10A 8/4885PDE4A 3/4885PDE4B 7/4885
US-20120213703-A1 RADIOLABELLED PDE10 LIGANDS PDE9A, PDE10A, PDE7A PDE10A 2/4885PDE4A 6/4885PDE4B 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.